According to a report, Innovent Bio (01801) saw its shares climb more than 3%, and as of press time, the stock was up 1.93% at HK$19.01, with a turnover of HK$1.226 billion.
On the news front, on November 9, according to a post on Innovent Bio's official WeChat account, the company announced today that the Phase III clinical study CREDIT-5 of its self-developed recombinant fully human anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody Sinitilimab Injection, conducted as a first-line monotherapy in Chinese participants with non-familial hypercholesterolemia and mixed hyperlipidemia, a multicenter, randomized, double-blind, placebo-controlled trial, has met its primary endpoint at week 12.
In this study, Sinitilimab Injection as a first-line monotherapy demonstrated significant lipid-lowering efficacy, with good safety and tolerability. Sinitilimab Injection is the first domestically marketed PCSK9 antibody drug in China and was officially included in the national medical insurance catalog on January 1, 2025.
The positive results of this Phase III clinical study mark another milestone breakthrough for Sinitilimab Injection in the field of hyperlipidemia treatment. Innovent Bio will soon submit a supplementary marketing authorization application to the National Medical Products Administration for the new indication, which is expected to provide a more convenient first-line treatment option for the hyperlipidemia population in China.
Comments